4H-Pyran-4-one, 3-hydroxy-2-methyl-, gallium salt (3:1) [ACD/Index Name]
Gallium tris(2-methyl-4-oxo-4H-pyran-3-olate) [ACD/IUPAC Name]
Galliumtris(2-methyl-4-oxo-4H-pyran-3-olat) [German] [ACD/IUPAC Name]
Tris(2-méthyl-4-oxo-4H-pyran-3-olate) de gallium [French] [ACD/IUPAC Name]
Off-white or light pink powder
NONH for all modes of transport
Specifications and Other Information of Our Gallium Maltolate CAS 108560-70-9
Under room temperature away from light
Gallium maltolate, by offering the advantages of enhanced bioavailability, potentially improved therapeutic properties and ease of administration, could significantly expand the therapeutic potential of gallium. To investigate the use/treatment of bladder cancer, lymphoma (not specified), multiple myeloma, paging disease and prostate cancer.
Gallium maltolate is a novel active formulation of gallium, a semimetal element, and a potent inhibitor of ribonucleotide reductase, an enzyme that promotes tumor growth. Gallium is also thought to concentrate in malignancies and sites of infection, and appears to favorably affect calcium deposition, making bones more resistant to degradation caused by cancer metastases.
This product is developed by our R&D company Caming Pharmaceutical Ltd (https://www.caming.com/).
This product is developed by our R&D company Watson International Ltd (https://www.watson-int.com/).